Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast Limited has aligned with the FDA on key requirements for filing a Biologics License Application for Revascor, a treatment for ischemic heart failure with reduced ejection fraction. This alignment follows a successful Type B meeting, and the company plans to file for accelerated approval by the end of the year, potentially strengthening its position in the regenerative medicine market and providing new treatment options for patients with severe heart conditions.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology to create therapies that release anti-inflammatory factors, significantly reducing damaging inflammation. Mesoblast’s RYONCIL is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and the company is also developing additional cell therapies for other inflammatory diseases. Mesoblast has established commercial partnerships in Japan, Europe, and China and holds a strong intellectual property portfolio with over 1,000 patents.
Average Trading Volume: 5,967,976
Technical Sentiment Signal: Hold
Current Market Cap: A$2.11B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.